Federated Hermes’s HilleVax HLVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-26,467
Closed -$52.7K 2168
2025
Q2
$52.7K Buy
26,467
+2,038
+8% +$3.73K ﹤0.01% 1634
2025
Q1
$35.4K Buy
24,429
+13,728
+128% +$25.4K ﹤0.01% 1667
2024
Q4
$22.2K Buy
10,701
+5,425
+103% +$10.2K ﹤0.01% 1762
2024
Q3
$9.29K Buy
5,276
+3,926
+291% +$10.1K ﹤0.01% 1814
2024
Q2
$19.5K Sell
1,350
-368
-21% -$5.06K ﹤0.01% 1720
2024
Q1
$28.6K Sell
1,718
-3
-0.2% -$48 ﹤0.01% 1684
2023
Q4
$27.6K Sell
1,721
-392
-19% -$5.21K ﹤0.01% 1717
2023
Q3
$28.4K Buy
2,113
+943
+81% +$13.3K ﹤0.01% 1741
2023
Q2
$20.1K Sell
1,170
-1,025
-47% -$15.9K ﹤0.01% 1774
2023
Q1
$36.3K Sell
2,195
-355
-14% -$5.68K ﹤0.01% 1764
2022
Q4
$42.7K Buy
+2,550
New +$46K ﹤0.01% 1734

Federated Hermes's HLVX Position: Q3 2025 in Review

Federated Hermes sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 26,467 shares — an estimated $52.7K sold.

Federated Hermes first reported a position in HLVX in Q4 2022 and held it in 11 quarters. The position peaked at $52.7K in Q2 2025. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.

  • Federated Hermes reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
  • Federated Hermes sold 26,467 HilleVax shares in Q3 2025, an estimated $52.7K.
  • Federated Hermes first reported a position in HilleVax in Q4 2022 and held it in 11 quarters.
  • Federated Hermes's HilleVax position peaked at $52.7K in Q2 2025.
  • 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.